A new paradigm for disease prevention
LSX are known for bringing life science investors together to assess and meet with the most promising up and coming biotech companies. When the first mRNA vaccines hit the market in 2020, our investors asked us to look at the resurgence of therapeutics targeting or made of RNA with the view to developing a high-level industry conference. And so, RNA Leaders was born!
The inaugural RNA Leaders Congress saw 50+ world-class speakers and over 300+ senior leaders from around the world join the most comprehensive and only RNA industry-focused event in Europe. The community came together for 2 days to hear the latest advances in RNA chemistry, get clinical updates from the companies developing new therapies, source the services partners who are helping to deliver drugs to patients and develop their network with over 500 partnering meetings!
The explosion of the RNA field continues, and RNA medicines are at a critical moment in time. mRNA vaccines dominate the headlines still in the wake of the COVID-19 pandemic. But huge advances are also being made in RNAi and antisense technologies as our understanding of the chemistry evolves. Delivery tools are increasingly sophisticated and impactful. Advances in genomics and gene editing are driving new approaches. And exciting work targeting RNA with small molecules and circular RNAs is emerging.
With that in mind, we can’t wait to bring the community together, face-to-face, for the first annual RNA Leaders USA Congress.
And in the words of Moderna’s CSO, Melissa Moore, “when I saw some other speakers who had been invited I felt this would be a really great place to connect with and network with my peers”.
So, if you’re passionate about all things RNA please join us, and more than 500 biotech, pharmaceutical, investment, regulatory and scientific professionals at the RNA Leaders USA Congress this October.